ACAD stock news today

Morgan Stanley cuts ACADIA Pharmaceuticals price target

Morgan Stanley reduced its price target on ACADIA Pharmaceuticals. The headline gives no figure for the new target or the reason behind the change.

Morgan Stanley keeps Equal-Weight on Acadia Pharmaceuticals, cuts target to $24

Morgan Stanley kept its Equal-Weight rating on Acadia Pharmaceuticals and reduced its price target to $24. The change reflects the firm's updated view on the stock.

Deutsche Bank trims its ACADIA Pharmaceuticals valuation to $27

Deutsche Bank lowered the level it assigns to ACADIA Pharmaceuticals shares, now $27. This is an analyst revision, not company news.

Acadia Pharmaceuticals to Share Remlifanserin Findings at 2026 CTAD Meeting

Acadia Pharmaceuticals plans to share findings on remlifanserin at the 2026 CTAD meeting. The company did not disclose the study results in advance.

Canaccord Genuity keeps Buy rating on Acadia Pharmaceuticals, lifts target to $38

Canaccord Genuity repeated its Buy rating on Acadia Pharmaceuticals and raised its price target to $38. The change reflects the firm's updated view on the stock.

RBC Capital Markets lifts its price target on Acadia Pharmaceuticals

RBC Capital Markets raised its price target on Acadia Pharmaceuticals. The update reflects the firm's revised view of the stock's value.

RBC Raises Its ACADIA Pharmaceuticals Target to $38 From $36

RBC now sees ACADIA Pharmaceuticals worth $38 a share, up from $36. The firm updated its valuation for the drugmaker.

RBC Capital keeps Outperform rating on Acadia Pharmaceuticals, lifts target to $38

RBC Capital repeated its Outperform call on Acadia Pharmaceuticals and moved its price target up to $38. The update reflects the firm's current view on the stock.

Acadia Pharmaceuticals Posts Q3 2026 Results

The drugmaker disclosed its financial performance for the three months ended in 2026's third quarter. The filing gives the company's latest earnings picture.

ACADIA Pharmaceuticals holds Q3 2026 earnings call

ACADIA Pharmaceuticals discussed its third-quarter 2026 results on an earnings call. The transcript covers the company's quarterly performance.

ACADIA Trims 2026 Revenue Range to $1.265B-$1.295B

The drugmaker gave a tighter full-year 2026 revenue outlook, now $1.265 billion to $1.295 billion versus the prior $1.240 billion to $1.300 billion. The midpoint lands close to the $1.272 billion consensus.

ACADIA Pharmaceuticals tops quarterly profit and revenue forecasts

The drugmaker posted third-quarter earnings and sales above analyst expectations. Per-share profit reached $0.31 versus a $0.20 estimate, while revenue of $342.291 million exceeded the $332.468 million projection.

AcadeMedia Posts Q1 2026/27 Financial Results

AcadeMedia has published its quarterly financial update for the first three months of fiscal 2026/27. The filing covers the education provider's results for that period.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

Needham Keeps Buy Rating on Acadia Pharmaceuticals, $35 Target

Needham repeated its buy rating on Acadia Pharmaceuticals and left its $35 price target unchanged. The analyst firm's stance on the stock stays the same.

UBS cuts Acadia Pharmaceuticals to Neutral, price target to $23

UBS lowered its rating on Acadia Pharmaceuticals to Neutral and reduced its price target to $23. The change reflects the analyst's updated view of the stock.

RBC Capital keeps Outperform rating on Acadia Pharmaceuticals, cuts price target to $36

RBC Capital reiterated its Outperform rating on Acadia Pharmaceuticals while reducing its price target to $36. The update reflects the analyst's revised expectations for the stock.

Acadia Pharmaceuticals receives USPTO notice of allowance for Rett syndrome patent application

Acadia Pharmaceuticals said the USPTO issued a notice of allowance for its patent application covering methods and compositions for treating Rett syndrome. The notice moves the application toward a granted patent.

ACADIA Pharmaceuticals shares fall after analysts cut price targets

Several analyst firms reduced their price targets on ACADIA Pharmaceuticals, and the stock traded lower. The cuts reflect revised expectations from those analysts.

Deutsche Bank keeps Buy rating on ACADIA Pharmaceuticals, cuts target to $31

Deutsche Bank reiterated its Buy rating on ACADIA Pharmaceuticals while reducing its price target to $31. The update reflects the bank's latest view on the stock.

HC Wainwright keeps Buy rating on ACADIA Pharmaceuticals, cuts target to $33

HC Wainwright & Co. reiterated its Buy rating on ACADIA Pharmaceuticals while lowering its price target to $33. The change reflects the firm's updated view on the stock.

Citizens keeps Market Outperform on ACADIA Pharmaceuticals, cuts target to $33

Citizens reiterated its Market Outperform rating on ACADIA Pharmaceuticals while reducing its price target to $33. The update reflects the firm's current view on the stock.

BMO Capital keeps Outperform rating on ACADIA Pharmaceuticals, cuts target to $34

BMO Capital reiterated its Outperform rating on ACADIA Pharmaceuticals while reducing its price target to $34. The change reflects the analyst's updated view on the stock.

Needham keeps Buy rating on ACADIA Pharmaceuticals, cuts price target to $35

Needham reiterated its Buy rating on ACADIA Pharmaceuticals while reducing its price target to $35. The analyst update changes the firm's outlook on the stock.

Citigroup keeps Buy rating on ACADIA Pharmaceuticals, cuts target to $33

Citigroup reiterated its Buy rating on ACADIA Pharmaceuticals while reducing its price target to $33. The change reflects the firm's updated view on the stock.

What is the latest news on ACAD?

Nov 13, 2026: Morgan Stanley cuts ACADIA Pharmaceuticals price target (Fiscal.ai) · Nov 13, 2026: Morgan Stanley keeps Equal-Weight on Acadia Pharmaceuticals, cuts target to $24 (Benzinga) · Nov 11, 2026: Deutsche Bank trims its ACADIA Pharmaceuticals valuation to $27 (Fiscal.ai)

What has ACAD filed with the SEC recently?

Oct 30, 2026: Acadia Pharmaceuticals Inc filed an insider trading report (Form 4) · Oct 23, 2026: Acadia Pharmaceuticals Inc filed a report on a major company event (Form 8-K)